This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

MEYER FRIEDMAN, M.D.

Arch Intern Med. 1941;67(5):921-938.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

With the introduction of the original prontosil (the hydrochloride of 4-sulfamido-2', 4'-diaminoazobenzene) by Domagk¹ and the confirmation of the action of sulfanilamide and its derivatives by other observers,² a new era in chemotherapy was begun. The discovery of sulfanilamide as the effective principle in the prontosil molecule and the widespread use of this drug in treatment of infections other than those due to the hemolytic streptococcus quickly followed. A further impetus was given to progress in this renascent field in 1938 by the clinical introduction of sulfapyridine (2-[paraaminobenzenesulfonamido] pyridine) by Whitby,³ who demonstrated its striking efficacy in treatment not only of infections due to the pneumococcus but also of those due to the hemolytic streptococcus. These initial observations of Whitby, like those of Domagk, were quickly and amply confirmed in the last several years by numerous workers.⁴

Despite this rapid advance in the treatment of various . . . [Full Text PDF of this Article]

Author Affiliations
With the Collaboration of Arthur Selzer, M.D., and Patricia McLean, B.A.; SAN FRANCISCO

From the Harold Brunn Institute for Cardiovascular Research, Mount Zion Hospital.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?